NR4A1 and breast carcinoma: Due to its widespread clinical use and robust evidence base, including randomized trials demonstrating that five years of tamoxifen treatment reduces breast cancer recurrence by approximately 40% and mortality by one-third, tamoxifen remains a cornerstone of adjuvant endocrine therapy in hormone receptor-positive breast cancer, particularly among premenopausal women [29,30].